FDA approves Endo Pharmaceuticals' Felodipine Extended-release Tablets

NewsGuard 100/100 Score
Nov 3 2011

Endo Pharmaceuticals (Nasdaq: ENDP) today announced that the U.S. Food and Drug Administration has approved Felodipine Extended-release Tablets USP, 2.5mg, 5mg and 10mg.  Qualitest Pharmaceuticals, the generic business unit of Endo Pharmaceuticals, will manufacture and distribute the Felodipine Extended-release Tablets.

Felodipine Extended-release Tablets USP are the generic version of AstraZeneca's Plendil® Extended-release Tablets.

The total sales for Felodipine in the U.S. for the 12 months ended June 30, 2011 were approximately $84 million, according to IMS Health.

SOURCE Endo Pharmaceuticals

Posted in: Pharmaceutical News

Tags: , , , , ,

Comments (0)

Suggested Reading

MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals
Common HIV drugs linked to reduced Alzheimer's disease risk
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain
New urine-based test improves identification of high-grade prostate cancer
Supply chain assessment and management, optimizing pharmaceutical supply chains
SCIEX’s Jose Castro-Perez Reveals How They're Setting New Standards in Mass Spectrometry
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
LabVantage celebrates customer success with record number of software deployments in FY 2024

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Lancet Commission predicts sharp increase in global prostate cancer cases